RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T20:56:00Z
Merck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholders
Fri 27 Sep 24, 04:31 AMMerck KGaA (MKGAF): Morgan Stanley is Bullish on This European AI Stock Now
Fri 16 Aug 24, 12:39 PMMerck KGaA Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Line
Sat 03 Aug 24, 08:05 AMMerck KGaA (ETR:MRK) Is Due To Pay A Dividend Of €2.20
Sun 28 Apr 24, 07:28 AMShareholders Will Most Likely Find Merck KGaA's (ETR:MRK) CEO Compensation Acceptable
Sat 20 Apr 24, 06:23 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 4287.00M | 3924.00M | 2630.00M | 1735.00M | 1461.00M |
| Minority interest | -14.00000M | -10.00000M | 71.00M | 73.00M | 33.00M |
| Net income | 3326.00M | 3055.00M | 1987.00M | 1320.00M | 3374.00M |
| Selling general administrative | 1306.00M | 1241.00M | 1188.00M | 1154.00M | 993.00M |
| Selling and marketing expenses | 4097.00M | 3714.00M | 3572.00M | 3653.00M | 3408.00M |
| Gross profit | 13705.00M | 12336.00M | 10699.00M | 10146.00M | 9454.00M |
| Reconciled depreciation | 2030.00M | 1762.00M | 1938.00M | 1944.00M | 1812.00M |
| Ebit | 4474.00M | 4179.00M | 2985.00M | 2120.00M | 1897.00M |
| Ebitda | 6744.00M | 5962.00M | 4729.00M | 4228.00M | 3709.00M |
| Depreciation and amortization | 2270.00M | 1783.00M | 1744.00M | 2108.00M | 1812.00M |
| Non operating income net other | - | - | - | 0.00000M | 0.00000M |
| Operating income | 4474.00M | 4179.00M | 2985.00M | 2120.00M | 1727.00M |
| Other operating expenses | 17480.00M | 15491.00M | 14724.00M | 13848.00M | 12965.00M |
| Interest expense | 235.00M | 272.00M | 387.00M | 476.00M | 339.00M |
| Tax provision | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M |
| Interest income | 71.00M | 46.00M | 39.00M | 71.00M | 60.00M |
| Net interest income | -164.00000M | -226.00000M | -348.00000M | -406.00000M | -280.00000M |
| Extraordinary items | - | - | - | 0.00000M | 0.00000M |
| Non recurring | - | - | - | 0.00000M | 0.00000M |
| Other items | - | - | - | 0.00000M | 0.00000M |
| Income tax expense | 948.00M | 859.00M | 637.00M | 440.00M | 368.00M |
| Total revenue | 22232.00M | 19687.00M | 17534.00M | 16152.00M | 14836.00M |
| Total operating expenses | 8953.00M | 8140.00M | 7889.00M | 7842.00M | 7583.00M |
| Cost of revenue | 8527.00M | 7351.00M | 6835.00M | 6006.00M | 5382.00M |
| Total other income expense net | -187.00000M | -255.00000M | -355.00000M | -385.00000M | -266.00000M |
| Discontinued operations | - | - | - | 28.00M | 2303.00M |
| Net income from continuing ops | 3339.00M | 3065.00M | 1994.00M | 1296.00M | 1093.00M |
| Net income applicable to common shares | 3326.00M | 3055.00M | 1987.00M | 1320.00M | 3374.00M |
| Preferred stock and other adjustments | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 48526.00M | 45362.00M | 41796.00M | 43811.00M | 36888.00M |
| Intangible assets | 7300.00M | 7612.00M | 7653.00M | 9175.00M | 7238.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 151.00M | 94.00M | 76.00M | 97.00M | 99.00M |
| Total liab | 22521.00M | 23946.00M | 24779.00M | 25898.00M | 19655.00M |
| Total stockholder equity | 25927.00M | 21338.00M | 16946.00M | 17865.00M | 17200.00M |
| Deferred long term liab | - | - | - | 0.00000M | 0.00000M |
| Other current liab | 6720.00M | 839.00M | 666.00M | 564.00M | 473.00M |
| Common stock | 565.00M | 565.00M | 565.00M | 565.00M | 565.00M |
| Capital stock | 565.00M | 565.00M | 565.00M | 565.00M | 565.00M |
| Retained earnings | 18463.00M | 15134.00M | 12378.00M | 11507.00M | 12525.00M |
| Other liab | 3808.00M | 5244.00M | 5763.00M | 5408.00M | 4457.00M |
| Good will | 18415.00M | 17004.00M | 15959.00M | 17141.00M | 13764.00M |
| Other assets | 1730.00M | 1932.00M | 1944.00M | 1820.00M | 1466.00M |
| Cash | 1398.00M | 1511.00M | 1110.00M | 541.00M | 2171.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 9513.00M | 10432.00M | 9231.00M | 11842.00M | 8517.00M |
| Current deferred revenue | - | 5555.00M | 4503.00M | 4692.00M | 4702.00M |
| Net debt | 9000.00M | 9255.00M | 10929.00M | 12578.00M | 6634.00M |
| Short term debt | 1198.00M | 2496.00M | 2294.00M | 4532.00M | 2198.00M |
| Short long term debt | 1073.00M | 2379.00M | 2182.00M | 4423.00M | 2196.00M |
| Short long term debt total | 10398.00M | 10766.00M | 12039.00M | 13119.00M | 8805.00M |
| Other stockholder equity | 6899.00M | 5639.00M | 4003.00M | 5793.00M | 16635.00M |
| Property plant equipment | 8203.00M | 7217.00M | 6421.00M | 6192.00M | 4811.00M |
| Total current assets | 12201.00M | 10982.00M | 9280.00M | 9003.00M | 9236.00M |
| Long term investments | - | - | - | 1437.82M | 1474.70M |
| Net tangible assets | 210.00M | -3278.00000M | -6666.00000M | -8494.00000M | -3801.00000M |
| Short term investments | 244.00M | 112.00M | 29.00M | 29.00M | 8.00M |
| Net receivables | 5776.00M | 5365.00M | 4771.00M | 4994.00M | 4194.00M |
| Long term debt | 8834.00M | 7928.00M | 9418.00M | 8129.00M | 6605.00M |
| Inventory | 4632.00M | 3900.00M | 3294.00M | 3342.00M | 2764.00M |
| Accounts payable | 1595.00M | 1542.00M | 1768.00M | 2054.00M | 1144.00M |
| Total permanent equity | - | - | - | 0.00000M | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | 0.00000M | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | 0.00000M | 0.00000M |
| Accumulated other comprehensive income | - | - | - | 0.00000M | 0.00000M |
| Additional paid in capital | - | - | - | 0.00000M | 0.00000M |
| Common stock total equity | - | - | - | 0.00000M | 0.00000M |
| Preferred stock total equity | - | - | - | 0.00000M | 0.00000M |
| Retained earnings total equity | - | - | - | 0.00000M | 0.00000M |
| Treasury stock | - | - | - | 0.00000M | 0.00000M |
| Accumulated amortization | - | - | - | 0.00000M | 0.00000M |
| Non currrent assets other | 432.00M | 271.00M | 151.00M | 171.00M | 169.00M |
| Deferred long term asset charges | - | - | - | 0.00000M | 0.00000M |
| Non current assets total | 36325.00M | 34380.00M | 32516.00M | 34808.00M | 27652.00M |
| Capital lease obligations | 491.00M | 459.00M | 439.00M | 567.00M | 4.00M |
| Long term debt total | - | - | - | 0.00000M | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2743.00000M | -200.00000M | 62.00M | -56.00000M | -20.00000M |
| Change to liabilities | 101.00M | 433.00M | 7.00M | 201.00M | 104.00M |
| Total cashflows from investing activities | -2743.00000M | -1578.00000M | -1340.00000M | -6153.00000M | 2191.00M |
| Net borrowings | -588.00000M | -1747.00000M | -835.00000M | 2591.00M | -2056.00000M |
| Total cash from financing activities | -1555.00000M | -2504.00000M | -1522.00000M | 1902.00M | -2825.00000M |
| Change to operating activities | -166.00000M | 75.00M | -233.00000M | -238.00000M | -89.00000M |
| Net income | 3339.00M | 3065.00M | 1994.00M | 1324.00M | 3396.00M |
| Change in cash | -45.00000M | 544.00M | 574.00M | -1389.00000M | 1581.00M |
| Begin period cash flow | 1899.00M | 1355.00M | 781.00M | 2170.00M | 589.00M |
| End period cash flow | 1854.00M | 1899.00M | 1355.00M | 781.00M | 2170.00M |
| Total cash from operating activities | 4259.00M | 4616.00M | 3477.00M | 2856.00M | 2219.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 2030.00M | 1762.00M | 1938.00M | 1944.00M | 1812.00M |
| Other cashflows from investing activities | -1.00000M | -0.30000M | 2.00M | -130.00000M | -130.00000M |
| Dividends paid | -239.00000M | -181.00000M | -168.00000M | -162.00000M | 755.00M |
| Change to inventory | -604.00000M | -472.00000M | -85.00000M | -324.00000M | -172.00000M |
| Change to account receivables | -413.00000M | -310.00000M | -84.00000M | -47.00000M | -109.00000M |
| Sale purchase of stock | - | - | - | 0.00000M | 0.00000M |
| Other cashflows from financing activities | 3185.00M | 283.00M | 5918.00M | 4554.00M | 393.00M |
| Change to netincome | 217.00M | 128.00M | 130.00M | 42.00M | -2643.00000M |
| Capital expenditures | 1806.00M | 1421.00M | 1563.00M | 1021.00M | 1016.00M |
| Change receivables | - | - | - | 0.00000M | 0.00000M |
| Cash flows other operating | - | - | - | 0.00000M | 0.00000M |
| Exchange rate changes | - | - | - | 0.00000M | 0.00000M |
| Cash and cash equivalents changes | - | - | - | 0.00000M | 0.00000M |
| Change in working capital | -1082.00000M | -274.00000M | -395.00000M | -408.00000M | -266.00000M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -28.00000M | 63.00M | -60.00000M | -4.00000M | -2723.00000M |
| Free cash flow | 2453.00M | 3195.00M | 1914.00M | 1835.00M | 1203.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MKGAF MERCK Kommanditgesellschaft auf Aktien |
-3.015 2.08% | 142.05 | 21.73 | 14.95 | 3.16 | 2.15 | 3.56 | 12.82 |
| ZTS Zoetis Inc |
-0.52 0.30% | 175.04 | 40.18 | 30.96 | 10.67 | 17.60 | 11.27 | 26.18 |
| MKKGY Merck KGaA ADR |
-0.29 0.98% | 29.33 | 21.25 | 14.93 | 3.10 | 2.14 | 3.60 | 12.98 |
| TAK Takeda Pharmaceutical Co Ltd ADR |
-0.33 2.42% | 13.29 | 32.67 | 11.53 | 0.01 | 0.87 | 0.02 | 0.07 |
| TKPHF Takeda Pharmaceutical Co. Ltd. |
- -% | 25.55 | 32.60 | 11.59 | 0.01 | 0.88 | 0.02 | 0.07 |
Merck KGaA operates as a science and technology company in Germany. The company's Life Science segment offers a range of products, including reagents, consumable, devices, instruments, software, and services for scientific discovery, as well as provides lab water instruments, consumables and services, microbiology and biomonitoring, products, test assays, analytical reagents, and flow cytometry kits and instruments for pharma and biotech, industrial and testing, academics and government, and diagnostic sectors. Its Healthcare segment designs and develops medicines and intelligent devices for treatment of various therapeutics, such as oncology, neurology and immunology, endocrinology, and general medicines. The company's Electronic segment provides semiconductor solutions, such as semiconductor materials, delivery systems and services, and intermolecular services for semiconductor and polymer removal chemistries applications; and display solutions comprising liquid crystals, OLED and quantum materials, reactive mesogens, photoresist materials, smart antenna, and dynamic liquid crystal glazing products, as well as offers liviFlex, a flexible platform, which offers a range of display materials. This segment also provides surface solution, such as cosmetics, effect pigments, and functional solutions; architecture solutions, including switchable windows; and automotive solutions. In addition, it has strategic alliances with Pfizer Inc. and GlaxoSmihKline plc to develop and commercialize active ingredients in immune-oncology; in-licensing agreement with Debiopharm International SA for developing drug candidates for the treatment of head and neck cancer; and out-licensing agreement with MoonLake Immunotherapeutics AG for developing a drug candidate for the treatment of inflammatory diseases. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Frankfurter Strasse 250, Darmstadt, Germany, 64293
| Name | Title | Year Born |
|---|---|---|
| Ms. Belen Garijo Lopez M.D. | Chair of Exec. Board & CEO | 1960 |
| Dr. Marcus Kuhnert | CFO & Member of Exec. Board | 1968 |
| Dr. Kai Beckmann | CEO of Electronics & Member of the Exec. Board | 1965 |
| Mr. Peter Guenter | CEO of Healthcare Bus. & Member of Exec. Board | 1962 |
| Dr. Matthias J. Heinzel | CEO of Life Science Sector & Member of Exec. Board | 1967 |
| Mr. Gerhard Schmitz | Head of Global Accounting | 1963 |
| Mr. Dirk Toepfer | Chief Information Officer | NA |
| Mr. Constantin Fest | Head of Investor Relations | 1977 |
| Dr. Friederike Rotsch | Group Gen. Counsel and Head of Group Legal & Compliance | 1972 |
| Ms. Barbara Weiland | Chief Compliance Officer | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...